Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis

Renal cell carcinoma (RCC) is the sixth most common diagnosis of cancer in men and the eighth in women in United States with an estimated 63,990 new cases and 14,400 deaths occurred in the 2017 [1]. In Europe, the incidence and the mortality of RCC are estimated to be 71,739 and 31,293 cases per years, respectively [2,3]

Source: Cancer Treatment Reviews - August 20, 2018 Category: Cancer & Oncology Authors: Roberto Iacovelli, Chiara Ciccarese, Emilio Bria, Davide Bimbatti, Emanuela Fantinel, Claudia Mosillo, Iolanda Bisogno, Matteo Brunelli, Giampaolo Tortora, Camillo Porta Source Type: research